| Jo-1 Positive (n=40) | Controls (n=80) | P value* | |
|---|---|---|---|
| Age, mean years (range) | 53 (19–86) | 52 (17–87) | – |
| Sex (% female) | 70% | 79% | 0.37 |
| Dead | 13% | 4% | 0.12 |
| Current or previous malignancy | 10% | 10% | 1.0 |
| Raynauds | 17.5% | 6.3% | 0.10 |
| Inflammatory arthritis | 20% | 19% | 1.0 |
| Clinical myositis diagnosis | 5% | 1.3% | 0.26 |
| CPK >1000 units/liter | 5% | 1.3% | 0.26 |
| Interstitial lung disease | 12.5% | 6% | 0.30 |
| CT chest done during study period | 17/40 | 20/80 | 0.06 |
| ANA (≥1:100) | 18/38 (47.4%) | 22/79 (27.8%) | 0.06 |
| RF | 8/25 (32%) | 12/44 (27.3%) | 0.78 |
| CCP | 0/19 (0%) | 3/33 (9.1%) | 0.54 |
| Anti-dsDNA (Crithidia +ve) | 7.5% | 1.3% | 0.11 |
| Scl70 | 7.5% | 0% | ** |
| SSA/Ro | 10% | 0% | ** |
| SSB/La | 10% | 0% | ** |
| RNP | 10% | 0% | ** |
*Fisher's exact test, two tailed. **Statistical analyses were not done on these comparisons as by definition controls were negative for ENA antibodies.